PCI Pharma Services (PCI) announced the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK. The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others. PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labeling – which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet. PCI is a strong supporter of the advanced use of aggregation to support product security, realizing the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.
PCI’s site in Tredegar, South Wales, UK already offers excellence in potent manufacturing services for customers globally, and this new Serialization technology further strengthens its comprehensive offering. This investment in the Tredegar facility is part of a significant global initiative to develop the Serialization services across PCI’s global network, which will ultimately exceed more than 90 lines.
“This is an important addition to the site’s capabilities. Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD,” Jim Neville, Director of Operations, Tredegar, said.